| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 04/04/2006 | US7022311 Powdery inhalational preparations and process for producing the same |
| 04/04/2006 | US7021309 Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin |
| 04/04/2006 | US7021031 Process for making pre-formed objects |
| 04/04/2006 | CA2281962C Emulsion including a hydrophilic thickening compound and a thickening copolymer, compounds including the said emulsion, and uses |
| 04/04/2006 | CA2265532C Process for producing solid dosage forms by extrusion |
| 04/04/2006 | CA2259407C Drug delivery devices and process of manufacture |
| 04/04/2006 | CA2257305C Marking rapidly disintegrating dosage forms |
| 04/04/2006 | CA2257303C Biconvex rapidly disintegrating dosage forms |
| 04/04/2006 | CA2181072C Estradiol penetration enhancers |
| 03/31/2006 | WO2005027875A1 Particles |
| 03/31/2006 | CA2576410A1 Particles |
| 03/30/2006 | WO2006034467A2 Biocompatible hydrogel compositions |
| 03/30/2006 | WO2006034397A2 Coating composition |
| 03/30/2006 | WO2006034383A1 Viscoelastic solution or gel formulation, and methods of treating a body site with the same |
| 03/30/2006 | WO2006034255A2 Methods of device-assisted drug delivery |
| 03/30/2006 | WO2006034253A1 Low-emission adhesive composition based on a solvent |
| 03/30/2006 | WO2006034239A2 Antimicrobial mesoporous silica nanoparticles |
| 03/30/2006 | WO2006034147A2 Compositions and methods for the preparation and administration of poorly water soluble drugs |
| 03/30/2006 | WO2006034080A2 Formulation comprising itraconazole |
| 03/30/2006 | WO2006033948A2 Sustained local anesthetic composition containing preferably a sugar ester such as saib |
| 03/30/2006 | WO2006033911A2 Methods of administering water-soluble prodrugs of propofol |
| 03/30/2006 | WO2006033713A2 Methods for ciprofloxacin inhalation |
| 03/30/2006 | WO2006033698A2 Tissue matrix system |
| 03/30/2006 | WO2006033686A1 Angiogenesis factor and biological material |
| 03/30/2006 | WO2006033604A1 A metered medication dose |
| 03/30/2006 | WO2006033433A1 Wound remedy |
| 03/30/2006 | WO2006033296A1 Novel block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient |
| 03/30/2006 | WO2006032762A2 Pharmaceutical composition comprising a solid dispersion with a polymer matrix containing a continuous polydextrose phase and a continuous phase of a polymer other than polydextrose |
| 03/30/2006 | WO2006032676A1 Pharmaceutical composition comprising roflumilast or the n-oxide of roflumilast |
| 03/30/2006 | WO2006032675A1 Aqueous pharmaceutical preparation comprising roflumilast |
| 03/30/2006 | WO2006032624A1 Pharmaceutical composition for transdermal administration |
| 03/30/2006 | WO2006032464A2 Method of treatment of acute exudative skin lesions and composition useful therefor |
| 03/30/2006 | WO2006032386A1 Lyophilisate containing n-diaminomethylene-2-methyl-4,5-di-(methylsulfonyl)-benzamide |
| 03/30/2006 | WO2006032364A1 Lozenges based on mucolytic drugs for inflammatory diseases of the mouth and pharynx |
| 03/30/2006 | WO2006032144A1 Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using fucans from various echinoderm sources |
| 03/30/2006 | WO2006032143A1 Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans |
| 03/30/2006 | WO2006032089A1 Sustained release pharmaceutical composition |
| 03/30/2006 | WO2006017374A3 Nutritional supplement composition and method |
| 03/30/2006 | WO2006007856A3 Acidic solid oral compositions without erosive potential in saliva and method for determining erosive potential in saliva |
| 03/30/2006 | WO2006006691A3 Solid dispersion of a p38 map kinase inhibitor |
| 03/30/2006 | WO2005123034A8 Microparticulate systems for the oral administration of biologically active substances |
| 03/30/2006 | WO2005105049A8 Orally disintegrating tablets and methods of manufacture |
| 03/30/2006 | WO2005102279A3 Controlled gap techniques for fiber optics devices |
| 03/30/2006 | WO2005102275A3 Galantamine salts, method of producing it and nasal composition thereof |
| 03/30/2006 | WO2005102274A3 Method of stabilizing disordered cefovecin sodium salt |
| 03/30/2006 | WO2005082331A3 Extended release tablets of clarithromycin |
| 03/30/2006 | WO2005079751A3 Oral pharmaceutical compositions of candesartan cilexetil |
| 03/30/2006 | WO2005070398A3 Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents |
| 03/30/2006 | WO2005060940A3 Method for the production of a solid, orally applicable pharmaceutical composition |
| 03/30/2006 | WO2005055955A3 DOSING METHODS FOR ß-D-2’,3’-DIDEOXY-2’,3’-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY |
| 03/30/2006 | WO2005049024A3 Solid pharmaceutical preparation form |
| 03/30/2006 | WO2005048993A3 Minimization of drug oxidation in drug irradiated excipients formulations |
| 03/30/2006 | WO2005044246A3 Controlled release analgesic suspensions |
| 03/30/2006 | WO2005044243A3 Transdermal analgesic systems having reduced abuse potential |
| 03/30/2006 | WO2005037911A3 Heterofunctional copolymers of glycerol and polyethylene glycol, their conjugates and compositions |
| 03/30/2006 | WO2005032512A3 Capsules of multilayered neutral polymer films associated by hydrogen bonding |
| 03/30/2006 | WO2005030164A3 Improved controlled release dosage form including a banded engine |
| 03/30/2006 | WO2005020912A3 Delivery of immune response modifier compounds |
| 03/30/2006 | WO2005013896A3 Programmed immune responses using a vaccination node |
| 03/30/2006 | WO2004089298A3 5-htp composition |
| 03/30/2006 | US20060069382 Delivery device |
| 03/30/2006 | US20060069203 core blocks formed of 2-methacryloyloxyethyl-2'-trimethylammonium ethylphosphate inner salt (MPC) and terminal blocks formed of 2-(diisopropylamino)ethyl methacrylate; ability to undergo changes, when exposed to selected stimuli, often reversibly. gelled by changing the pH ; for drug delivery systems |
| 03/30/2006 | US20060069177 Homogenous dispersion of thermoplastic or elastomeric polymer/oligomer with reactive end groups, monofunctional and/or bifunctional acrylate or methacrylate monomer, multifunctional acrylated/methacrylated monomer having more than two functional groups, photoinitiator, and organic and inorganic filler |
| 03/30/2006 | US20060069162 Transparent eye drops containing latanoprost |
| 03/30/2006 | US20060069114 Liquid pharmaceutical formulations of palonosetron |
| 03/30/2006 | US20060069113 Analgesic compositions containing buprenorphine |
| 03/30/2006 | US20060069033 Use of poly-amminopyrrolecarboxamides alone or in combination with a cyclodextrin in the prophylaxis and treatment of animal parasitosis |
| 03/30/2006 | US20060069018 Treating lung diseases selected from acute pneumonia, pulmonary fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), and asthma by administering (E)-[5-[2-[1-phenyl-1-(3-pyridyl)methylideneaminoxy]ethyl]-7,8-dihydronaphthalen-1-yloxy]acetic acid or a salt thereof |
| 03/30/2006 | US20060069013 Pharmaceutical preparations comprising acid-stabilised insulin |
| 03/30/2006 | US20060069010 Detoxification depot for Alzheimer's disease |
| 03/30/2006 | US20060068080 Combinatorial discovery of nanomaterials |
| 03/30/2006 | US20060068043 Aqueous solution of flavonoids and anthocyanins |
| 03/30/2006 | US20060068034 nose spray lipophilic medicament comprising tetrahydrocannabinol and cannabidiol, and cannabis plant extract as the drug substance; free from self emulsifying agent and/or a fluorinated propellant; administered by a pump action spray |
| 03/30/2006 | US20060068021 Sustained-release microencapsulated delivery system |
| 03/30/2006 | US20060068019 Coated polyunsaturated fatty acid-containing particles and coated liquid pharmaceutical-containing particles |
| 03/30/2006 | US20060068018 Extended release formulation |
| 03/30/2006 | US20060068017 Extended release formulation |
| 03/30/2006 | US20060068016 Paticulate product comprising pantethine |
| 03/30/2006 | US20060068015 Particulate or in solid dosage forms; a combination of fibrate and HMG CoA reductase inhibitor statins or a pharmaceutically active salts, in dissolved form in order to ensure suitable bioavailability of both active ingredients upon oral administration |
| 03/30/2006 | US20060068014 Ionic hydrogels with controlled aqueous fluid absorption |
| 03/30/2006 | US20060068013 Non-adhesive elastic gelatin matrices |
| 03/30/2006 | US20060068012 Process for preparing poly (vinyl alcohol) drug delivery devices with humidity control |
| 03/30/2006 | US20060068011 Simultaneous encapsulation technique for use in pharmaceutical compositions |
| 03/30/2006 | US20060068010 Method for improving the bioavailability of orally delivered therapeutics |
| 03/30/2006 | US20060068009 Modified release ibuprofen dosage form |
| 03/30/2006 | US20060068008 Lyophilized pharmaceutical compositions |
| 03/30/2006 | US20060068007 Class of surfactant-like materials |
| 03/30/2006 | US20060068006 Edible holographic products, particularly pharmaceuticals and methods and apparatus for producing same |
| 03/30/2006 | US20060068005 Chewable electrolyte tablet |
| 03/30/2006 | US20060068004 Buccal delivery of sea cucumber tablets |
| 03/30/2006 | US20060068003 System for increasing compliance with medication regime |
| 03/30/2006 | US20060068002 Extended release formulation |
| 03/30/2006 | US20060068001 Administering antidepressant venlafaxine hydrochloride in extended release form; lower incidence of nausea and vomiting |
| 03/30/2006 | US20060068000 24 hour extended release unit dosage of antidepressant venlafaxine hydrochloride, and a degradable coating so that venlafaxine is released in a peak, followed by a protracted, substantially linear decrease |
| 03/30/2006 | US20060067999 Spheroids comprise a core of venlafaxine and a binder or filler; daily dosage with side effect reduction of nausea and vomiting |
| 03/30/2006 | US20060067998 Liposomal curcumin for treatment of cancer |
| 03/30/2006 | US20060067997 Phospholipid complexes of lexitropsins, their preparation and use in therapeutic formulations |
| 03/30/2006 | US20060067996 Preventing/treating signs of skin stress/aging by bioenergetically modifying acupuncture points of the face or neck |
| 03/30/2006 | US20060067995 Topical and/or transdermal bioactive compound delivery system |
| 03/30/2006 | US20060067994 System for providing therapy to a body |